Friedberg Ezra M 4

What Happened
Ezra M. Friedberg, a director of Pelthos Therapeutics, sold a total of 558 shares of Pelthos common stock in open-market transactions on April 2, 2026. The sales were in two blocks: 293 shares at a weighted-average price of $20.51 for proceeds of $6,010, and 265 shares at a weighted-average price of $21.36 for proceeds of $5,661 — about $11,671 total. These were sales (S), not purchases.

Key Details

• Transaction date: April 2, 2026; Form 4 filed April 6, 2026 (timely — within two business days).
• Reported prices and execution details:
  • 293 shares sold at a weighted avg of $20.51 (executed in multiple trades at $20.30–$20.78).
  • 265 shares sold at a weighted avg of $21.36 (executed in multiple trades at $21.31–$22.03).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes of note:
  • Sale made pursuant to a Rule 10b5-1 trading plan adopted Dec 16, 2025 to satisfy estimated tax obligations related to RSU vesting. (F1)
  • Weighted-average prices reported; the filer will provide full trade-level details on request. (F2, F3)
  • Mr. Friedberg is manager of two LLCs that hold shares; he may be deemed beneficial owner of those record holdings but disclaims beneficial ownership except for his pecuniary interest. (F4)

Context
A Rule 10b5-1 plan is a prearranged trading plan that allows insiders to sell shares at set times or under predetermined conditions; such sales are often routine (for example, to cover tax withholding on vested awards) and do not necessarily reflect the insider’s view of the company. Sales (S) are generally less informative about insider sentiment than purchases, which can be a stronger bullish signal.